Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA.,Childrens National Medical Centre, DC 20010 USA
Coley, William (författare)
Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA.,Childrens National Medical Centre, DC 20010 USA
Phadke, Aditi (författare)
Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA.,Childrens National Medical Centre, DC 20010 USA
Diaz-Gallo, Lina-Marcela (författare)
Karolinska Inst, Dept Med Solna, Theumatol Unit, SE-17176 Stockholm, Sweden.,Karolinska Institute, Sweden
Bottai, Matteo (författare)
Karolinska Inst, Inst Environm Med, Unit Biostat, SE-17176 Stockholm, Sweden.,Karolinska Institute, Sweden
Nennesmo, Inger (författare)
Karolinska Inst, Dept Lab Med, SE-17176 Stockholm, Sweden.,Karolinska Institute, Sweden
Chemin, Karine (författare)
Karolinska Inst, Dept Med Solna, Theumatol Unit, SE-17176 Stockholm, Sweden.,Karolinska Institute, Sweden
Herrath, Jessica (författare)
Karolinska Inst, Dept Med Solna, Theumatol Unit, SE-17176 Stockholm, Sweden.,Karolinska Institute, Sweden
Johansson, Karin (författare)
Karolinska Inst, Dept Med Solna, Theumatol Unit, SE-17176 Stockholm, Sweden.,Karolinska Institute, Sweden
Wikberg, Anders (författare)
Karolinska Inst, Dept Med Solna, Theumatol Unit, SE-17176 Stockholm, Sweden.,Karolinska Institute, Sweden
Ytterberg, A. Jimmy (författare)
Karolinska Inst, Dept Med Solna, Theumatol Unit, SE-17176 Stockholm, Sweden.;Karolinska Inst, Dept Med Biochem & Biophys, SE-17176 Stockholm, Sweden.
Zubarev, Roman A. (författare)
Karolinska Inst, Dept Med Biochem & Biophys, SE-17176 Stockholm, Sweden.,Karolinska Institute, Sweden
Danielsson, Olof (författare)
Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Div Neurol, Linkoping, Sweden.
Krystufkova, Olga (författare)
Charles Univ Prague, Fac Med 1, Inst Rheumatol, Prague, Czech Republic.;Charles Univ Prague, Fac Med 1, Dept Rheumatol, Prague, Czech Republic.,Charles University of Prague, Czech Republic; Charles University of Prague, Czech Republic
Vencovsky, Jiri (författare)
Charles Univ Prague, Fac Med 1, Inst Rheumatol, Prague, Czech Republic.;Charles Univ Prague, Fac Med 1, Dept Rheumatol, Prague, Czech Republic.,Charles University of Prague, Czech Republic; Charles University of Prague, Czech Republic
Landegren, Nils (författare)
Uppsala universitet,Autoimmunitet,Karolinska Inst, Dept Med Solna, Expt Endocrinol, SE-17176 Stockholm, Sweden.,Karolinska Institute, Sweden; Uppsala University, Sweden
Wahren-Herlenius, Marie (författare)
Karolinska Inst, Dept Med Solna, Expt Rheumatol Unit, SE-17176 Stockholm, Sweden.,Karolinska Institute, Sweden
Padyukov, Leonid (författare)
Karolinska Inst, Dept Med Solna, Theumatol Unit, SE-17176 Stockholm, Sweden.,Karolinska Institute, Sweden
Kämpe, Olle (författare)
Uppsala universitet,Autoimmunitet,Karolinska Inst, Dept Med Solna, Expt Endocrinol, SE-17176 Stockholm, Sweden.
Lundberg, Ingrid E. (författare)
Karolinska Inst, Dept Med Solna, Theumatol Unit, SE-17176 Stockholm, Sweden.,Karolinska Institute, Sweden
Jimmy Ytterberg, A. (författare)
Karolinska Institute, Sweden; Karolinska Institute, Sweden
Kampe, Olle (författare)
Karolinska Institute, Sweden; Uppsala University, Sweden
Mutations of the gene encoding four-and-a-half LIM domain 1 (FHL1) are the causative factor of several X-linked hereditary myopathies that are collectively termed FHL1-related myopathies. These disorders are characterized by severe muscle dysfunction and damage. Here, we have shown that patients with idiopathic inflammatory myopathies (IIMs) develop autoimmunity to FHL1, which is a muscle-specific protein. Anti-FHL1 autoantibodies were detected in 25% of IIM patients, while patients with other autoimmune diseases or muscular dystrophies were largely anti-FHL1 negative. Anti-FHL1 reactivity was predictive for muscle atrophy, dysphagia, pronounced muscle fiber damage, and vasculitis. FHL1 showed an altered expression pattern, with focal accumulation in the muscle fibers of autoantibody-positive patients compared with a homogeneous expression in anti-FHL1-negative patients and healthy controls. We determined that FHL1 is a target of the cytotoxic protease granzyme B, indicating that the generation of FHL1 fragments may initiate FHL1 autoimmunity. Moreover, immunization of myositis-prone mice with FHL1 aggravated muscle weakness and increased mortality, suggesting a direct link between anti-FHL1 responses and muscle damage. Together, our findings provide evidence that FHL1 may be involved in the pathogenesis not only of genetic FHL1-related myopathies but also of autoimmune IIM. Importantly, these results indicate that anti-FHL1 autoantibodies in peripheral blood have promising potential as a biomarker to identify a subset of severe IIM.
Ämnesord
MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Basic Medicine (hsv//eng)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)